To obtain cambinol-based SIRT2-specific inhibitors devoid of SIRT1 or SIRT3 inhibition, authors from the Fred Hutchinson Cancer Research Center (Seattle, WA, USA), who previously developed cambinol [15], recently investigated open-chain SIRT2Is derived from cambinol [126]. Here, SIRT2 is linked to cancer.